Skip to main content
IMMUTEP LIMITED logo

IMMUTEP LIMITED — Investor Relations & Filings

Ticker · IMM ISIN · AU000000IMM6 LEI · 529900OL6C5CY5P8BH38 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,780 across all filing types
Latest filing 2024-12-04 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IMM

About IMMUTEP LIMITED

https://www.immutep.com

Immutep Limited focuses on the development of novel immunotherapy treatments for cancer and autoimmune diseases, specifically targeting the Lymphocyte Activation Gene-3 (LAG-3) pathway. The company's lead therapeutic candidate is eftilagimod alpha (efti), a first-in-class soluble LAG-3 protein and MHC class II agonist. Efti functions by activating antigen-presenting cells, which in turn triggers a robust T cell response against tumors. It is currently being evaluated in clinical trials for multiple solid tumor indications, including non-small cell lung cancer and head and neck squamous cell carcinoma, frequently in combination with other anti-cancer agents. The pipeline also includes IMP761, an agonist antibody designed to suppress overactive immune responses in autoimmune conditions. The company's technology utilizes the LAG-3 protein's role in immune regulation to create targeted therapeutic interventions.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - IMM 6 pages 19.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G notification, which is a standard ASX form used to notify the issue, conversion, or payment up of unquoted equity securities. It details the issuance of performance rights under an employee incentive scheme, including the number of securities issued, issue date, and recipients (including key management personnel). The document is a regulatory announcement about a securities issuance event rather than a full financial report or earnings release. It does not contain financial statements or management discussion but focuses on capital changes related to securities issuance. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (6044 characters) and content confirm it is not merely an announcement of a report but a substantive notification of a capital event.
2024-12-04 English
Immutep Investor Update 8 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Update November 2024' and contains detailed information about the company's clinical strategy, market opportunity, and ongoing Phase III trial collaboration with MSD for a lung cancer treatment. It includes extensive discussion of clinical trial data, market analysis, and strategic positioning. The content is a detailed presentation aimed at investors, focusing on financial and strategic aspects rather than a formal regulatory filing or financial report. There is no indication that this is an official annual or quarterly report, audit report, or earnings release. It is not a transcript of a call, nor a voting or dividend announcement. The document is clearly an investor-focused presentation with detailed strategic and clinical information, consistent with the definition of an Investor Presentation (IP). The length (15,000 characters) and depth of content support this classification with high confidence.
2024-11-25 English
Immutep AGM 2024 - Chairman's Address 4 pages 203.5KB
AGM Information Classification · 95% confidence The document is titled 'Immutep’s AGM 2024 Chairman’s Address' and is dated 22 November 2024. It is addressed to shareholders and provides an overview of the company's progress during the last financial year, including clinical trial updates, regulatory achievements, financial position, and future outlook. The content is typical of a chairman's speech delivered at an Annual General Meeting (AGM). There is no detailed financial statement or comprehensive annual report data, nor is it a brief announcement or a transcript of a call. The document is lengthy (over 10,000 characters) and contains substantive content related to the AGM. Therefore, it fits the category of AGM Information (AGM-R).
2024-11-21 English
Immutep AGM 2024 - CEO's Presentation 16 pages 1.6MB
AGM Information Classification · 100% confidence The document is titled "Immutep AGM 2024 Presentation 22 November 2024" and contains detailed slides about the company's business update, clinical programs, pipeline, milestones, and strategy. It is explicitly described as a presentation aid for the Annual General Meeting (AGM). The content includes forward-looking statements, company overview, clinical trial updates, and strategic outlook, typical of an investor or shareholder presentation at an AGM. There is no indication that this is a full annual report, earnings release, or regulatory filing. The document length (15,000 characters) and detailed slide content support it being a presentation rather than a brief announcement or certification. Therefore, the document fits the category of AGM Information (AGM-R).
2024-11-21 English
Results of Meeting 2 pages 141.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'RESULTS OF ANNUAL GENERAL MEETING' and explicitly states it provides the results of the AGM held on 22 November 2024. It references compliance with section 251AA(2) of the Corporations Act 2001 and ASX Listing Rule 3.13.2, which govern disclosure of voting results. The content includes detailed voting outcomes for resolutions passed at the AGM, including proxy votes and percentages. There is no indication that this is the full AGM report or presentation materials, but rather the official announcement of the voting results. The document length is 4643 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM report or presentation. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-11-21 English
Change in substantial holding 3 pages 96.0KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604' and references the Corporations Act 2001, Section 671B, which pertains to notices of change of interests of substantial holders. The content details changes in voting power and relevant interests of a substantial holder (Regal Funds Management Pty Limited and its associates) in the company IMMUTEP LTD. It includes dates of acquisition, number of securities affected, and voting power percentages. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of 'Major Shareholding Notification' (Code: MRQ). The document is 8465 characters long, contains detailed data on shareholding changes, and is not merely an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2024-11-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.